KALA
KALA BIOยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KALA Profile
Kala Bio, Inc.
A commercial-stage biopharmaceutical company that developing innovative therapies for diseases of the eye
1167 Massachusetts Avenue, Arlington, MA 02476
--
KALA BIO, Inc., was incorporated on July 7, 2009 under the laws of the State of Delaware as Hanes Newco, Inc. The company changed its name to Kala Pharmaceuticals, Inc., on December 11, 2009. The Company is a biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for the treatment of rare and serious anterior and posterior eye diseases. The company believes that these two key features enable the uniform distribution of drug particles on the mucosal surface and significantly increase drug delivery to target tissues by increasing the fluidity of drug particles through mucus and preventing drug particles from being captured and eliminated by mucus. The company has applied MPP technology to create a nanosuspension of Baibaopu calcium acetate, or LE, a corticosteroid designed for ocular applications, resulting in two drug candidates in Phase 3 clinical development, KPI-121 1.0% for the treatment of inflammation and pain after ophthalmic surgery and KPI-121 0.25% for the temporary relief of signs and symptoms of dry eye.
